298 related articles for article (PubMed ID: 30564301)
1. Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in
Patkar N; Kodgule R; Kakirde C; Raval G; Bhanshe P; Joshi S; Chaudhary S; Badrinath Y; Ghoghale S; Kadechkar S; Khizer SH; Kannan S; Shetty D; Gokarn A; Punatkar S; Jain H; Bagal B; Menon H; Sengar M; Khattry N; Tembhare P; Subramanian P; Gujral S
Oncotarget; 2018 Nov; 9(93):36613-36624. PubMed ID: 30564301
[TBL] [Abstract][Full Text] [Related]
2. Measurable residual disease detected by flow cytometry independently predicts prognoses of NPM1-mutated acute myeloid leukemia.
Zhang YW; Su L; Tan YH; Lin H; Liu XL; Liu QJ; Sun JN; Zhang M; Du YZ; Song F; Han W; Gao SJ
Ann Hematol; 2023 Feb; 102(2):337-347. PubMed ID: 36378304
[TBL] [Abstract][Full Text] [Related]
3. Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.
Zhou Y; Othus M; Walter RB; Estey EH; Wu D; Wood BL
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1615-1620. PubMed ID: 29684564
[TBL] [Abstract][Full Text] [Related]
4. Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
Patkar N; Kakirde C; Shaikh AF; Salve R; Bhanshe P; Chatterjee G; Rajpal S; Joshi S; Chaudhary S; Kodgule R; Ghoghale S; Deshpande N; Shetty D; Khizer SH; Jain H; Bagal B; Menon H; Khattry N; Sengar M; Tembhare P; Subramanian P; Gujral S
Leukemia; 2021 May; 35(5):1392-1404. PubMed ID: 33558666
[TBL] [Abstract][Full Text] [Related]
5. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
6. Minimal/Measurable Residual Disease Monitoring in
Forghieri F; Comoli P; Marasca R; Potenza L; Luppi M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404199
[TBL] [Abstract][Full Text] [Related]
7. Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after Allogeneic Transplantation.
Getta BM; Devlin SM; Levine RL; Arcila ME; Mohanty AS; Zehir A; Tallman MS; Giralt SA; Roshal M
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1064-1071. PubMed ID: 28315400
[TBL] [Abstract][Full Text] [Related]
8. Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study.
Hirsch P; Lambert J; Bucci M; Deswarte C; Boudry A; Lambert J; Fenwarth L; Micol JB; Terré C; Celli-Lebras K; Thomas X; Dombret H; Duployez N; Preudhomme C; Itzykson R; Delhommeau F
Blood Cancer J; 2024 Jun; 14(1):97. PubMed ID: 38871702
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
10. Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia-Real-World Context.
Patkar N; Kakirde C; Bhanshe P; Joshi S; Chaudhary S; Badrinath Y; Ghoghale S; Deshpande N; Kadechkar S; Chatterjee G; Kannan S; Shetty D; Gokarn A; Punatkar S; Bonda A; Nayak L; Jain H; Bagal B; Menon H; Sengar M; Khizer SH; Khattry N; Tembhare P; Gujral S; Subramanian P
Front Oncol; 2019; 9():450. PubMed ID: 31263671
[No Abstract] [Full Text] [Related]
11. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
12. Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML.
Tsai CH; Tang JL; Tien FM; Kuo YY; Wu DC; Lin CC; Tseng MH; Peng YL; Hou MF; Chuang YK; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
Blood Adv; 2021 May; 5(10):2456-2466. PubMed ID: 33999144
[TBL] [Abstract][Full Text] [Related]
13. Measurable Residual Disease Detected by Multiparameter Flow Cytometry and Sequencing Improves Prediction of Relapse and Survival in Acute Myeloid Leukemia.
Liu FJ; Cheng WY; Lin XJ; Wang SY; Jiang TY; Ma TT; Zhu YM; Shen Y
Front Oncol; 2021; 11():677833. PubMed ID: 34094982
[TBL] [Abstract][Full Text] [Related]
14. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
[TBL] [Abstract][Full Text] [Related]
15. Detection of NPM1 Mutations in Acute Myeloid Leukemia by using Drop-Off Droplet Digital PCR and its Clinical Application.
Jin Y; Xu ZJ; Yu D; Xia PH; Yao DM; Yuan Q; Li T; Xiang HL; Ma JC; Wen XM; Lin J; Qian J
Clin Lab; 2023 Nov; 69(11):. PubMed ID: 37948486
[TBL] [Abstract][Full Text] [Related]
16. The predictive value of minimal residual disease when facing the inconsistent results detected by real-time quantitative PCR and flow cytometry in NPM1-mutated acute myeloid leukemia.
Gao MG; Ruan GR; Chang YJ; Liu YR; Qin YZ; Jiang Q; Jiang H; Huang XJ; Zhao XS
Ann Hematol; 2020 Jan; 99(1):73-82. PubMed ID: 31768677
[TBL] [Abstract][Full Text] [Related]
17. Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory.
Blombery P; Jones K; Doig K; Ryland G; McBean M; Thompson E; Yannakou CK; Westerman D
Arch Pathol Lab Med; 2018 May; 142(5):606-612. PubMed ID: 29425073
[TBL] [Abstract][Full Text] [Related]
18. Comparison of RNA- and DNA-based methods for measurable residual disease analysis in NPM1-mutated acute myeloid leukemia.
Pettersson L; Johansson Alm S; Almstedt A; Chen Y; Orrsjö G; Shah-Barkhordar G; Zhou L; Kotarsky H; Vidovic K; Asp J; Lazarevic V; Saal LH; Fogelstrand L; Ehinger M
Int J Lab Hematol; 2021 Aug; 43(4):664-674. PubMed ID: 34053184
[TBL] [Abstract][Full Text] [Related]
19. Measurable Residual Disease Monitoring by Locked Nucleic Acid Quantitative Real-Time PCR Assay for
Kao HW; Kuo MC; Huang YJ; Chang H; Hu SF; Huang CF; Hung YS; Lin TL; Ou CW; Lien MY; Wu JH; Chen CC; Shih LY
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551690
[TBL] [Abstract][Full Text] [Related]
20. Time point-dependent concordance and prognostic significance of flow cytometry and real time quantitative PCR for measurable/minimal residual disease detection in acute myeloid leukemia with t(8;21)(q22;q22.1).
Shang L; Cai X; Sun W; Cheng Q; Mi Y
Cytometry B Clin Cytom; 2022 Jan; 102(1):34-43. PubMed ID: 34232569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]